A peptidoglycan-associated lipoprotein of about 15 kilodaltons was purified from the outer membranes of Haemophilus influenzae by using nondenaturing detergents. To assess its vaccine potential, rabbit antiserum to the purified protein was obtained. 
Haemophilus influenzae organisms are a major pathogen of humans, both adults and children. H. influenzae type b (Hib) is a common causative agent of meningitis of young children (23) , and nontypable H. influenzae is regularly implicated in sinusitis (8) , otitis media (5), neonatal sepsis (29) , and bronchitis (21) .
A vaccine composed of the capsule of Hib, polyribosyl ribotol phosphate (PRP), has been licensed. This vaccine is effective in children over 18 months of age but is ineffective in younger children. Vaccines composed of saccharideprotein conjugates are being evaluated in field trials, and results suggest that the conjugates are immunogenic in infants (4) . However, the conjugate vaccines as now formulated are not effective against nontypable H. influenzae. These problems have led investigators to study other H. influenzae antigens for their vaccine potential. One of these antigens, an approximately 16,000-dalton outer membrane protein (OMP) called P6 by some investigators, has been shown to be present in every H. influenzae isolate examined, both typable and nontypable (20) , and is reported to be antigenically conserved among strains (18) . Recent reports have indicated that antibodies which react with P6 are present in human serum and that these antibodies are bactericidal against nontypable H. influenzae (19) . Munson and Granoff (17) isolated P6 by using sodium dodecyl sulfate (SDS) and high salt. When they immunized rabbits with a P6-cell wall complex, they reported that the anti-P6 antibody was protective against the Hib strain from which the P6 was isolated.
P6 remains associated with the peptidoglycan after extraction of a protein-cell wall complex with SDS at 37°C (17) and recently has been reported to contain fatty acids (G. A. Weinberg, D. Towler, and R. S. Munson, Abstr. Annu. Meet. Amer. Soc. Microbiol. 1987, K142, p. 226). Thus the P6 OMP can be classified as a peptidoglycan-associated lipoprotein (PAL; for a review of PALs, see reference 15) .
In this manuscript we describe the isolation and purification of an approximately 15-kilodalton PAL from the outer membranes of H. influenzae by using nondenaturing deter-* Corresponding author.
gents. In a separate manuscript, the chemical and physical properties of this protein will be described and the protein will be characterized as a PAL (G. W. Zlotnick, V. T. Sanfilippo, J. A. Mattler, D. H. Kirkley, R. A. Boykins, and R. Seid, manuscript in preparation). To assess its vaccine potential, specific rabbit antiserum to the purified protein was prepared and used to determine (i) the distribution of bactericidal epitopes among a variety of Hib isolates from various geographic areas, (ii) the potential protective activity of anti-PAL antibody against multiple Hib clinical isolates, and (iii) the effect, if any, of anti-PAL antibody on the bactericidal and protective activities of anti-PRP antibody.
MATERIALS AND METHODS Bacteria. Clinical isolates of Hib and nontypable H. influenzae were kindly provided by Porter Anderson, Rochester, N.Y., Eric Hansen, Dallas, Tex., William Albritton, Saskatoon, Saskatchewan, Canada, and Robert Daum, New Orleans, La. H. influenzae isolates were subcultured once by overnight incubation at 37°C on brain heart infusion agar (BHI; Difco Laboratories, Detroit, Mich.) supplemented with hemin (Sigma Chemical Co., St. Louis, Mo.) at 10 ,ug/ml and NAD (Sigma) at 2 pug/ml (BHI-XV). Isolates were stored without further passage at -70°C in BHI containing 20% glycerol.
Purification of PAL. PAL was purified from Hib strain Eagan grown in BHI-XV broth medium. After incubation at 37°C with aeration, cells were harvested by centrifugation and frozen at -20°C. Frozen cells were thawed at 37°C, and a 20% (wt/vol) suspension made in 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), pH 7.4, containing 1 mM disodium EDTA (buffer A). The cell suspension was homogenized by sonication of 100-mI samples with a Branson model 350 sonifier cell disruptor (Branson Sonic Power, Danbury, Conn.) at 60% power for 5 min on ice. Unbroken cells were removed by centrifugation at 10,000 x g for 5 min at 4°C. Unbroken cells were suspended in half the original volume of buffer A and sonicated as before. Remaining unbroken cells were removed by centrifugation, and the supernatants from the low-speed centrifugations were pooled. The supernatants were adjusted to 0.5 M NaCI and centrifuged at 300,000 x g for 1 h at 4°C. The cell envelope pellet obtained from this centrifugation was suspended in 10 mM HEPES, pH 7.4 (buffer B), adjusted to 1% sodium lauroyl sarcosinate (sarcosyl), and extracted at room temperature for 30 min. Sarcosyl-insoluble material was pelleted by centrifugation at 300,000 x g for 30 min at 4°C, and the sarcosyl extraction was repeated.
Sarcosyl-insoluble material was suspended in 50 mM Tris hydrochloride (pH 8.0)-5 mM EDTA (buffer C) and extracted twice with a final concentration of 1% (wt/vol) Zwittergent 3-16 for 30 min at room temperature followed by centrifugation as above. Zwittergent-insoluble material was extracted twice more with 1% sarcosyl for 30 min at 23°C in buffer C. The remaining insoluble material was suspended in buffer C at one-fifth the volume of the original suspension and stored at 4°C.
The insoluble material from above was pelleted by centrifugation at 300,000 x g for 30 min at 4°C. (Fig. 1A) . LOS contamination of the purified protein was assayed by silver staining after SDS-PAGE. The sensitivity of the assay for LOS was 2.5 ng.
Purified 15K PAL contained <2.5 ng of LOS as determined by silver stain when 10 jig of protein was assayed (Fig. 1B) .
Specificity of anti-PAL antiserum. Hyperimmune rabbit anti-PAL antiserum was analyzed by Western blot analysis (Fig. 2) . The antiserum at a dilution of 1:500 reacted with the purified 15K PAL (Fig. 2, lane 2) and with the 15K PAL in 20 ,ug of an Hib cell envelope preparation (Fig. 2, lane 3) (Fig. 2, lane 1) . Biologic activity of mixed anti-PRP and anti-PAL antisera. The biologic activity of antisera containing a mixture of anti-PAL and anti-PRP antibodies was evaluated with both the in vitro bactericidal assay and the infant-rat model. Bactericidal effects of the pooled antisera were compared with the activity of each antiserum alone ( Table 5 ). The dilutions shown in Table 5 are final dilutions of each antiserum. Anti-PRP at dilutions of 1:1,600 or greater or anti-PAL at dilutions of 1:160 or greater were not bactericidal for Hib strain Eagan. However, when both antisera diluted past their respective bactericidal endpoint titers were mixed together, bactericidal activity was restored. The bactericidal activity of the mixed antisera was dependent upon the concentration of each antiserum; increasing the dilution of either one removed bactericidal activity. The bactericidal activity of the mixed antisera appeared to be additive.
Protective activities of mixed anti-PRP and anti-PAL were examined in the infant-rat model (Table 6 ). Anti-PRP antiserum and anti-PAL antiserum were titered to obtain their protective endpoints against Hib strain Eagan as described above. For example, anti-PRP antibody protected six of six rats at a dilution of 1:1,000, but only two of six rats at a dilution of 1:2,000 (Table 6 ). Anti-PAL antibody protected three of six rats at a dilution of 1:90, but only one of six rats at a dilution of 1:100 (Table 6 ). When infant rats were passively immunized with a mixture containing protective amounts of anti-PRP (1:1,000) and nonprotective amounts of anti-PAL (1:100), six of six rats were protected. These data indicate that the anti-PAL antiserum had no blocking effect on the anti-PRP antibody. When rats were passively immunized with a mixture of both antisera diluted beyond their (17) .
In the present study, efforts were made to purify a peptidoglycan-associated OMP free of LOS without the use of SDS or denaturing conditions as previously described (17, 18) . The protein isolated was free from LOS contamination (Fig. 1B, lane 1) (17, 18) .
Previous studies investigating the biological activity of polyclonal anti-PAL antibody were conducted by using the homologous strain or a very limited number of strains. The results presented in this study show that polyclonal antisera against a 15K PAL from Hib is bactericidal against a wide variety of Hib clinical isolates from widely dispersed geographic locations and isolated at different dates (Table 3) . Although the bactericidal titer of the antiserum varied from strain to strain, with some isolates being less sensitive and others more sensitive than the homologous strain, Hib strain Eagan, 181 of 182 clinical Hib isolates were killed.
Bactericidal activity of antibody directed against somatic antigens of H. influenzae has been shown to be affected by the relative amount of LOS that the strains produce. When Hib are exposed to low-molecular-weight serum components, they undergo a phenotypic shift in which the amount of LOS produced is greatly increased (10) . This shift reduced, but did not eliminate, the bactericidal activity of anti-somatic antigen antisera, but not of anti-PRP antisera. Experiments to determine the ability of anti-PAL to protect infant rats against phenotypically'shifted organisms have not been done. However, the organisms used in the animal protection experiments presented'here were virulent; 26 of 27 control animals were killed, and the anti-PAL antiserum was protective in the infant-rat model against multiple virulent Hib clinical isolates (Table 4) .
The reasons for the failure of anti-PAL to kill one of the (12) . The vaccine potential of PAL to prevent infections caused by H. influenzae would be seriously compromised if antibody to it interfered with anti-PRP. The results presented here suggest that this is not a problem with anti-PAL antiserum, since both bactericidal (Table 5 ) and protective ( 
